Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

icu medical inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid, unspecified form - unii:33x04xa5at), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698), monobasic potassium phosphate (unii: 4j9fj0hl51) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37, phosphate ion - unii:nk08v8k8hr) - ionosol mb and 5% dextrose injection is indicated for intravenous administration to infants for treatment of dehydration, acidosis, diarrhea, and burns, but only after administration of an initial priming solution: 15 ml of 5% dextrose and 0.45% sodium chloride injection/kg of body weight. in adults, ionosol mb and 5% dextrose injection is indicated postoperatively for intravenous fluid and electrolyte maintenance therapy, with a small amount of carbohydrate calories for reducing catabolism of endogenous protein reserves. solutions containing potassium are contraindicated in diseases where high potassium levels may be encountered.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

icu medical inc. - dextrose, unspecified form (unii: iy9xdz35w2) (dextrose, unspecified form - unii:iy9xdz35w2), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium acetate anhydrous (unii: nvg71zz7p0) (sodium cation - unii:lyr4m0nh37), sodium gluconate (unii: r6q3791s76) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838) - normosol-r and 5% dextrose injection is indicated for replacement of acute extracellular fluid volume losses in surgery, trauma, burns or shock. normosol-r and 5% dextrose also can be used as an adjunct to restore a decrease in circulatory volume in patients with moderate blood loss. the solution is not intended to supplant transfusion of whole blood or packed red cells in the presence of uncontrolled hemorrhage or severe reductions of red cell volume. none known.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

icu medical inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - dextrose injection 20%, 30%, 40%, 50% and 70%, mixed with amino acids or other compatible intravenous fluids, is indicated as a source of calories for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. the use of dextrose injection is contraindicated in patients: risk summary there are no data with dextrose injection in pregnant women. in addition, animal reproduction studies have not been conducted with dextrose. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk consider parenteral nutrition in cases of severe maternal malnutrition where nutritional requirements cannot be fulfilled by the enteral route because of the risks to the fetus associated with severe malnutrition, including preterm delivery, low birth weight, intrauterine growth restriction, congenital malformations, and perinatal mortality. there are no data regarding the presence of dextrose in human milk, the effects on a breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for dextrose injection and any potential adverse effects on the breastfed infant from dextrose injection or from the underlying maternal condition. neonates, especially those born premature and with low birth weight are at increased risk of developing hypo – or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose infusions to ensure adequate glycemic control in order to avoid potential long term adverse effects. hypoglycemia in the newborn can cause prolonged seizures, coma and brain damage. hyperglycemia has been associated with intraventricular hemorrhage, late onset bacterial and fungal infection, retinopathy of prematurity, necrotizing enterocolitis, bronchopulmonary dysplasia, prolonged length of hospital stay, and death. plasma electrolyte concentrations should be closely monitored in the pediatric population as this population may have impaired ability to regulate fluids and electrolytes. in very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage. because of immature renal function, preterm infants receiving prolonged treatment with dextrose injection, may be at risk aluminum toxicity [see warnings and precautions (5.6)] . patients, including pediatric patients, may be at risk for parenteral nutrition associated liver disease (pnald) [see warnings and precautions (5.7)] . clinical studies of dextrose injection did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from other younger patients. other reported clinical experience has not identified differences in responses between the elderly and younger patients.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

henry schein, inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - 25% dextrose injection is indicated in the treatment of acute symptomatic episodes of hypoglycemia in the neonate or older infant to restore depressed blood glucose levels and control symptoms. other drugs, such as epinephrine and glucagon, should be considered in patients unresponsive or intolerant to dextrose (glucose). oral feeding of dextrose may be necessary in infants with frequently recurring hypoglycemic episodes or to prevent recurrences due to hyperinsulinemia. 25% dextrose injection also provides a minimal source of carbohydrate calories. a concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

covetrus - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - dextrose monohydrate 50 g in 100 ml - for use in cattle as an aid in the treatment of uncomplicated primary ketosis.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

vettek - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - dextrose monohydrate 50 g in 100 ml - for use as an aid in the treatment of acetonemia (ketosis) in cattle. for animal use only

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

baxter healthcare corporation - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - dextrose and sodium chloride injection is indicated as a source of water, electrolytes and calories. dextrose and sodium chloride injection is contraindicated in patients with: risk summary appropriate administration of dextrose and sodium chloride injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations. animal reproduction studies have not been conducted with dextrose and sodium chloride injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary sodium is present in human breast milk. there are no data on the effects of dextrose and sodium chloride injection on a breastfed infant or the effects on milk producti

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

baxter healthcare corporation - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - dextrose monohydrate 5 g in 100 ml

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

b. braun medical inc. - dextrose (unii: iy9xdz35w2) (dextrose - unii:iy9xdz35w2) - dextrose 5 g in 100 ml

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

radix laboratories, inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - - for use as a supplemental nutritive source of dextrose in cattle.